263 related articles for article (PubMed ID: 10534163)
21. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.
Erkiliç S; Aydin A; Koçer NE
Endocr Pathol; 2002; 13(3):207-11. PubMed ID: 12446919
[TBL] [Abstract][Full Text] [Related]
22. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the follicular patterned thyroid lesions based on the WHO 2022 criteria with an emphasis on the grey-zone lesions.
Misra S; Dhawan S; Badwal S; Sengupta A; Khosla A; Agarwal SK; Rao S
Ann Diagn Pathol; 2024 Aug; 71():152282. PubMed ID: 38522359
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
25. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
Sahoo S; Hoda SA; Rosai J; DeLellis RA
Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
[TBL] [Abstract][Full Text] [Related]
26. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
29. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma.
Schelfhout LJ; Van Muijen GN; Fleuren GJ
Am J Clin Pathol; 1989 Nov; 92(5):654-8. PubMed ID: 2479256
[TBL] [Abstract][Full Text] [Related]
30. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
31. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
[TBL] [Abstract][Full Text] [Related]
32. Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification.
Bizzarro T; Martini M; Capodimonti S; Straccia P; Lombardi CP; Pontecorvi A; Larocca LM; Rossi ED
Cancer Cytopathol; 2016 Oct; 124(10):699-710. PubMed ID: 27717284
[TBL] [Abstract][Full Text] [Related]
33. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
34. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
35. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
36. Cytopathology of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A comparative study with similar patterned papillary thyroid carcinoma variants.
Mahajan S; Agarwal S; Kocheri N; Jain D; Mathur SR; Iyer VK
Cytopathology; 2018 Jun; 29(3):233-240. PubMed ID: 29638022
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
38. Sonographic and cytologic differences of NIFTP from infiltrative or invasive encapsulated follicular variant of papillary thyroid carcinoma: A Review of 179 Cases.
Yang GCH; Fried KO; Scognamiglio T
Diagn Cytopathol; 2017 Jun; 45(6):533-541. PubMed ID: 28332339
[TBL] [Abstract][Full Text] [Related]
39. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma?
Cameselle-Teijeiro J; Chan JK
Mod Pathol; 1999 Apr; 12(4):400-11. PubMed ID: 10229505
[TBL] [Abstract][Full Text] [Related]
40. Role of Ultrasound in Predicting Tumor Invasiveness in Follicular Variant of Papillary Thyroid Carcinoma.
Hahn SY; Shin JH; Oh YL; Kim TH; Lim Y; Choi JS
Thyroid; 2017 Sep; 27(9):1177-1184. PubMed ID: 28699414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
